[ENT cancers and genomics].
ENT cancers in France - with the fourth rank after the breast, colon and prostate localizations - represent on important problem of public health. Survival at five years reaches a maximum in spite of undeniable therapeutic progress, in particular with the targeted treatments associated to conventional cytotoxic drugs. The studies in progress still make it possible to hope for new predictive and prognostic biological markers, but the complexity of these parameters, as well as the needs for heavy and expensive equipment to explore them, require a unification of the efforts and means. It is the major objective of the cooperative program PACOR.
Milano
Gérard
G
Laboratoire d'Oncopharmacologie, CRLCC de Nice, Centre Antoine-Lacassagne, France.
D014408:Biomarkers, Tumor / Q000032:analysis; D023281:Genomics; D006801:Humans; D010039:Otorhinolaryngologic Neoplasms / Q000175:diagnosis / Q000235:genetics*
D014408:Biomarkers, Tumor